<DOC>
	<DOCNO>NCT02375984</DOCNO>
	<brief_summary>The purpose protocol determine whether autologous TIL infuse conjunction systemic high-dose IL-2 non-myeloablative chemotherapy cyclophosphamide fludarabine cause consistent durable objective response patient metastatic melanoma John Wayne Cancer Institute ( JWCI ) .</brief_summary>
	<brief_title>A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes ( TIL ) Metastatic Melanomas</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Inclusion Criteria Patients must metastatic melanoma resectable metastatic lesion sufficient size willing undergo resection experimental purpose . Patients must &gt; 18 year age . Patients must measurable disease measure Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion ( addition resect lesion ) . Patients child bear potential must agree use effective form birth control study four month receive treatment . Clinical performance status Eastern Cooperative Oncology Group ( ECOG ) 01 . Absolute neutrophil count great 1000/mm3 without support filgrastim . Platelet count great 100,000/mm3 . Serum Alanine transaminase/Aspartate transaminase ( ALT/AST ) less three time upper limit normal . Serum creatinine less equal 1.6 mg/dl . Total bilirubin less equal 2 mg/dl , except patient Gilbert 's Syndrome must total bilirubin less 3 mg/dl . Patients must able understand sign Informed Consent document . Exclusion Criteria Tumor/TIL Harvest Exclusion Criteria All systemic , cytotoxic therapy ( include target therapy ) must stop least 5 week prior cell infusion ( see 2.1.3 ) . Women pregnant breastfeeding . Life expectancy less three month . Patients receive prior treatment anticytotoxic T lymphocyteassociated antigen 4 ( antiCTLA4 ) antibody exclude unless post antiCTLA4 antibody treatment colonoscopy normal normal colonic biopsy . Patients require immediate active treatment symptomatic Central Nervous System ( CNS ) lesion eligible treatment symptomatic lesion . Cell Infusion Exclusion Criteria Less 5 week elapse since prior systemic therapy time patient receives preparative regimen . All patient ' toxicity must recover grade 1 less specify eligibility criterion Section 2.1.1 . Patients may undergo minor surgical procedure focal palliative radiotherapy ( nontarget lesion ) within past 5 week , long toxicity recover grade 1 less specify eligibility criterion Section 2.1.1 . Women childbearing potential pregnant breastfeeding . Life expectancy less three month . Systemic steroid therapy equivalent 10mg/day prednisone . Hemoglobin le 8g/dl unable correct transfusion . Any active systemic infection , coagulation disorder active major medical illness cardiovascular , respiratory immune system , evidence positive stress thallium comparable test , myocardial infarction , cardiac arrhythmia , obstructive restrictive pulmonary disease . Any form primary secondary immunodeficiency . Must recover immune competence chemotherapy radiation therapy evidence normal Absolute Neutrophil Count ( ANC ) &gt; 1000/mm3 absence opportunistic infection . ( The experimental treatment evaluate protocol depends intact immune system . Patients decrease immune competence may less responsive experimental treatment susceptible toxicity . ) Seropositive HIV antibody . Patients active hepatitis B active hepatitis C. The following patient exclude inability receive high dose proleukin : Patients exclude history major EKG abnormality , symptom cardiac ischemia arrhythmia Left Ventricular Ejection Fraction ( LVEF ) &lt; 45 % cardiac stress test ( stress thallium , stress Multi Gated Acquisition Scan ( MUGA ) , dobutamine , echocardiogram stress test ) Patients prolonged history cigarette smoking symptom respiratory dysfunction exclude abnormal pulmonary function test evidence Forced Expiratory Volume one second Forced Expiratory Volume one second ( FEV1 ) &lt; 60 % predict . Patients receive prior treatment antiCTLA4 antibody exclude unless subsequent colonoscopy normal normal colonic biopsy ( rule colitis ) . Patients require immediate treatment symptomatic CNS lesion eligible treatment symptomatic lesion resolution symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>